SPPI - Spectrum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.50
-0.68 (-5.16%)
At close: 4:00PM EDT

12.72 +0.22 (1.72%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close13.18
Open13.24
Bid4.44 x 900
Ask13.75 x 2200
Day's Range12.49 - 13.33
52 Week Range12.49 - 25.29
Volume1,494,924
Avg. Volume1,499,032
Market Cap1.312B
Beta (3Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-18
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire4 days ago

    Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Francois Lebel, M.D., F.R.C.P.C. as Chief Medical Officer, effective November 5, 2018. “Dr. Lebel is an accomplished leader and has deep expertise in biopharmaceuticals with an emphasis in oncology drug development,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “Given his qualifications, we believe Dr. Lebel will add significant value to Spectrum and our clinical programs.

  • Business Wire25 days ago

    Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the 2018 Cantor Global Healthcare Conference being held in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • Business Wire28 days ago

    Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced preliminary poziotinib data from the University of Texas, MD Anderson Cancer Center Phase 2 non-small cell lung cancer (NSCLC) study which were released today during an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. The MD Anderson study is the single largest data set of patients with an exon 20 mutation in EGFR or HER2.

  • Business Wirelast month

    Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for first-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertion mutations in its current Phase 2 non-small cell lung cancer (NSCLC) clinical trial. Spectrum also announced that it has dosed the first patient in the expanded patient population.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure

    NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer

    HENDERSON, Nev.-- -- The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a disease control rate of 83% were reported Updated data will be presented in an oral ...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind International Bancshares, Morgan Stanley, Equity Residential, Hormel Foods, Spectrum Pharmaceuticals, and Cousins Properties — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of International ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th. The presentations will be webcast live and may be accessed by visiting Spectrum’s website at http://investor.sppirx.com/events-and-presentations. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • GlobeNewswire2 months ago

    AVANT DIAGNOSTICS ADDS TWO ESTEEMED, INTERNATIONALLY RECOGNIZED BOARD MEMBERS AND FILES ITS 2016 10-K IN PREPARATION OF GETTING CURRENT WITH THE SEC

    Avant Diagnostics, Inc. ("Avant" or the “Company”) (OTC Pink: AVDX), today announced the addition of two internationally known oncology experts, Dr. Rajesh Shrotriya, M.D. and Andy DeLaO, to its Board of Directors, the appointments to be effective on Tuesday, August 28, 2018. Dr. Rajesh Shrotriya, M.D., the former CEO and Chairman of Spectrum Pharmaceuticals (NASDAQ: SPPI), has over four decades of experience in the medical field, first as a dedicated physician and then as a pharmaceutical industry executive.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Alnylam Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update

    HENDERSON, Nev.-- -- An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA Both Phase 3 ROLONTIS ®    studies, RECOVER and ADVANCE, ...

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the second quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 9, ...

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU ...

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Business Wire4 months ago

    Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which showed that ROLONTIS had an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1. New safety data presented today also showed that the adverse events were not significantly different between two treatment arms.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.

  • Business Wire4 months ago

    Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee Health Science Center, and Executive Director, UT/West Cancer Center.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...

  • Business Wire5 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRE5 months ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Business Wire5 months ago

    CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.

  • Business Wire5 months ago

    Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed results from ADVANCE, a Phase 3 trial of ROLONTIS, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. “These data expand our understanding of the clinical profile of eflapegrastim and help establish it as a possible supportive care treatment option for the multitude of patients undergoing chemotherapy,” said Lee Schwartzberg, M.D., FACP, lead investigator, professor of medicine and division chief, hematology oncology, University of Tennessee Health Science Center, and executive director, UT/West Cancer Center.

  • Business Wire5 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. A live webcast of Spectrum’s presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRE6 months ago

    Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.